Changes in plasma lipids predict pravastatin efficacy in secondary prevention
Kaushala S Jayawardana, Piyushkumar A Mundra, Corey Giles, Christopher K Barlow, Paul J Nestel, Elizabeth H Barnes, Adrienne Kirby, Peter Thompson, David R Sullivan, Zahir H Alshehry, Natalie A Mellett, Kevin Huynh, Malcolm J McConville, Sophia Zoungas, Graham S Hillis, John Chalmers, Mark Woodward, Ian C Marschner, Gerard Wong, Bronwyn A Kingwell Show all
JCI Insight | AMER SOC CLINICAL INVESTIGATION INC | Published : 2019
Awarded by NHMRC
The LIPID study was supported by Bristol-Myers Squibb and the NHMRC (grants 211086, 358395). JC and MW are supported by an NHMRC program grant (1149987) and MW by an NHMRC fellowship (108026). This study was supported by an NHMRC grant (1029754) and the Operational Infrastructure Support Program of the Victorian government of Australia. We would like to thank the investigators of the LIPID and the ADVANCE studies and the patients who participated in these studies. We acknowledge Michelle Cinel and Ricardo Tan for their technical support in the lipidomic analyses. See the Supplemental Acknowledgments for the LIPID Study Investigators' details.